INTELLIA THERAPEUTICS INC. - COMMON STOCK

Intellia Therapeutics Receives European Union Orphan Drug Designation for NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema

14 Nov 2023 07:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress

09 Nov 2023 07:30:00 By Nasdaq GlobeNewswire

Intellia Presents New Interim Data from the Ongoing Phase 1 Study of NTLA-2001 at the 4th International ATTR Amyloidosis Meeting

02 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Intellia Therapeutics to Present Updated Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis and Hold Conference Call to Discuss Third Quarter 2023 Earnings in November

26 Oct 2023 07:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application to Initiate a Pivotal Phase 3 Trial of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

18 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Receives Priority Medicines (PRIME) Designation From the European Medicines Agency for NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema

13 Oct 2023 08:38:43 By Nasdaq GlobeNewswire

Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases

03 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress

03 Aug 2023 07:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2023 Earnings and Company Updates

27 Jul 2023 07:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Announces New Positive Clinical Data from Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema (HAE)

11 Jun 2023 08:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Announces Retirement of Jean-François Formela, M.D. From its Board of Directors

05 Jun 2023 16:01:00 By Nasdaq GlobeNewswire

Intellia Therapeutics to Present Updated Interim Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Hybrid Congress 2023

31 May 2023 07:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress

04 May 2023 07:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Releases 2023 Corporate Responsibility Report Highlighting the Advancement of its Environmental, Social & Governance (ESG) Priorities

01 May 2023 07:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2023 Earnings and Company Updates

27 Apr 2023 07:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Names Bill Chase to its Board of Directors

17 Apr 2023 16:01:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to NTLA-2002 for the Treatment of Hereditary Angioedema

21 Mar 2023 07:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for NTLA-2002, an In Vivo CRISPR-Based Investigational Therapy for the Treatment of Hereditary Angioedema (HAE)

02 Mar 2023 07:00:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Company Progress

23 Feb 2023 07:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2022 Earnings and Company Updates

16 Feb 2023 07:30:00 By Nasdaq GlobeNewswire